Nearly Half of Teen Obesity Prescriptions Never Filled, Study Reveals Troubling Gaps
Major study finds 43% of obesity medications prescribed to teens go unfilled, with Hispanic youth facing greatest barriers to access.
Summary
A comprehensive five-year study of nearly 1,200 adolescents and young adults found that 43% of prescribed obesity medications were never filled at pharmacies. The research revealed significant disparities, with Hispanic youth 39% less likely to receive their medications compared to white peers. Newer medications like semaglutide and tirzepatide had lower fill rates than older drugs like phentermine. Surprisingly, those with prescription drug coverage were twice as likely to fill prescriptions, highlighting insurance barriers. Despite obesity medication prescribing increasing each year from 2020-2025, actual dispensing rates declined over time, suggesting growing access problems that could impact long-term health outcomes for young people struggling with obesity.
Detailed Summary
This groundbreaking study exposes a critical gap in adolescent obesity treatment that could have lasting implications for lifelong health and longevity. Obesity in youth often persists into adulthood, increasing risks for diabetes, cardiovascular disease, and reduced lifespan.
Researchers analyzed electronic health records linked to pharmacy dispensing data from Nemours Children's Health, tracking 1,194 adolescents and young adults aged 12-20 who received prescriptions for obesity medications including semaglutide, liraglutide, phentermine, and tirzepatide between 2020-2025. The study excluded those with diabetes to focus specifically on obesity treatment.
The results revealed troubling disparities. Only 56.7% of prescribed obesity medications were ever filled. Hispanic youth faced the greatest barriers, being 39% less likely to fill prescriptions compared to non-Hispanic white peers. Newer GLP-1 medications like semaglutide and tirzepatide had significantly lower fill rates than older drugs like phentermine, likely due to cost and insurance coverage issues.
Counterintuitively, patients with prescription drug coverage were twice as likely to fill medications, while those with public or mixed insurance had better access than private insurance holders. Most concerning, despite increasing prescription rates each year, actual dispensing rates declined over the study period.
These findings have profound implications for health optimization and longevity. Early intervention in obesity can prevent decades of metabolic dysfunction, cardiovascular disease, and premature aging. The study highlights urgent needs for improved insurance coverage, reduced medication costs, and targeted interventions to address racial and ethnic disparities in healthcare access.
Key Findings
- 43% of obesity medications prescribed to teens and young adults were never filled at pharmacies
- Hispanic youth were 39% less likely to receive prescribed obesity medications than white peers
- Newer medications like tirzepatide had 55% lower fill rates than established drugs like phentermine
- Prescription drug coverage doubled the likelihood of medication access
- Medication dispensing rates declined over time despite increasing prescription rates
Methodology
Retrospective cohort study linking electronic health records to pharmacy dispensing data from Nemours Children's Health (2020-2025). Analyzed 1,194 adolescents and young adults aged 12-20 with obesity medication prescriptions, excluding those with diabetes. Used multilevel logistic regression to assess dispensing factors.
Study Limitations
Study limited to one healthcare system which may not represent national patterns. Excluded patients with diabetes, limiting generalizability. Did not assess reasons for non-dispensing or long-term health outcomes. Observational design cannot establish causation for disparities observed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.